Moderna says vaccine is safe for children ages 6 to 11
Moderna plans to submit data to FDA, EMA and other regulators in the near term.
Moderna says they plan to submit data to the U.S. Food and Drug Administration, European Medicines Agency and other global regulators in the near term.
The trial tested 4,753 children ages 6 to 11 and results showed a strong immune response one month after the second dose.
Common side effects found during the trial included fatigue, headache, fever, and injection site pain, says Moderna.